HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma-Reference-Cited by-同舟云学术

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma

Published:2019-09-25 Issue:12 Volume:8 Page:e1665976
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Malissen Nausicaa¹²^ORCID,Macagno Nicolas³^ORCID,Granjeaud Samuel¹^ORCID,Granier Clémence⁴,Moutardier Vincent⁵,Gaudy-Marqueste Caroline¹²^ORCID,Habel Nadia⁶^ORCID,Mandavit Marion⁴,Guillot Bernard⁷,Pasero Christine¹,Tartour Eric⁴,Ballotti Robert⁶^ORCID,Grob Jean-Jacques¹²,Olive Daniel¹

Affiliation:

1. Tumor Immunology Team, IBISA Immunomonitoring platform, Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix-Marseille University, Institut Paoli-Calmettes, Marseille, France

2. INSERM, CRCM, APHM, CHU Timone, Department of Dermatology and Skin Cancer, Aix Marseille University, Marseille, France

3. INSERM, MMG, APHM, CHU Timone, Department of Pathology, Aix Marseille University, Marseille, France

4. UMR_S970, HEGP, Centre de recherche cardio-vasculaire, Paris, France

5. APHM, CHU Nord, Department of Digestive surgery, Aix Marseille University, Marseille, France

6. INSERM U 1065, Team 1 Nice, Centre Méditerranéen de Médecine Moléculaire, Nice, France

7. Department of Dermatology, CHU Montpellier, Montpellier, France

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1665976

Reference57 articles.

1. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

3. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

4. The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma;Journal of Experimental & Clinical Cancer Research;2024-07-31

2. Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival;International Journal of Molecular Sciences;2024-06-22

3. The BTLA–HVEM axis restricts CAR T cell efficacy in cancer;Nature Immunology;2024-06

4. HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function;Cellular Oncology;2024-05-29

5. The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients;Frontiers in Immunology;2024-05-21